Literature DB >> 29357793

Vascular Risk Factors and Lesions of Vascular Nature in Magnetic Resonance as Predictors of Progression to Dementia in Patients with Mild Cognitive Impairment.

Raul Romero-Sevilla1, Ignacio Casado-Naranjo1,2, Juan Carlos Portilla-Cuenca1, Beatriz Duque-de San Juan1, Jose Manuel Fuentes2,3, Fidel Lopez-Espuela4.   

Abstract

BACKGROUND: Evidence of the effect of vascular risk factors and white matter lesions on the progression of mild cognitive impairment (MCI) to dementia is not conclusive.
OBJECTIVE: The study aimed to analyze the impact of these factors on MCI progression to dementia from a global perspective.
METHODS: Our study included a population of 105 patients with MCI.
RESULTS: After a mean follow-up period of 3.09 years (range, 2-3.79), 47 patients (44.76%) progressed to dementia: 32 (30.8%) to mixed dementia, 13 (12.5%) to probable AD, and 2 (1.9%) to vascular dementia. Total cholesterol levels (OR: 1.015 [1.003-1.028]) and LDL cholesterol levels (OR: 1.018 [1.004-1.032]) increased the risk of progression to dementia. Cystatin C was a protective factor against progression to dementia (OR: 0.119 [0.015-0.944], p = 0.044). During the second year of follow-up, the presence of subcortical white matter hyperintensities increased the risk of progression to dementia (OR: 5.854 [1.008- 33.846]). Subcortical and periventricular white matter hyperintensities were also associated with an increased risk of progression to dementia during the second year of follow-up (OR: 3.130 [1.098-8.922] and OR: 3.561 [1.227-10.334], respectively). The same was true for silent infarcts (OR: 4.308 [1.480- 12.500]).
CONCLUSION: A high percentage of patients progressed to dementia. Total cholesterol, LDL cholesterol, and white matter hyperintensities were found to be associated with MCI progression to dementia. In contrast, cystatin C was shown to be a protective factor against progression to dementia. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Alzheimer's disease; Mild cognitive impairment; cholesterol; dementia; vascular risk factor; white matter hyperintensities.

Mesh:

Substances:

Year:  2018        PMID: 29357793     DOI: 10.2174/1567205015666180119100840

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  4 in total

1.  Low Diastolic Blood Pressure and Cognitive Decline in Korean Elderly People: The Korean Longitudinal Study on Cognitive Aging and Dementia.

Authors:  Dongyun Lee; Bong-Jo Kim; Ji Won Han; Tae Hui Kim; Kyung Phil Kwak; Kayoung Kim; Shin Gyeom Kim; Jeong Lan Kim; Tae Hyun Kim; Seok Woo Moon; Jae Young Park; Joon Hyuk Park; Seonjeong Byun; Seung Wan Suh; Ji Young Seo; Yoonseop So; Seung-Ho Ryu; Jong Chul Youn; Kyoung Hwan Lee; Dong Young Lee; Dong Woo Lee; Seok Bum Lee; Jung Jae Lee; Ju Ri Lee; Hyeon Jeong; Hyun-Ghang Jeong; Jin Hyeong Jhoo; Kyuhee Han; Jong Woo Hong; Jong Bin Bae; Ki Woong Kim
Journal:  Psychiatry Investig       Date:  2020-01-25       Impact factor: 2.505

2.  Changes in Serum Cystatin C Levels and the Associations With Cognitive Function in Alzheimer's Disease Patients.

Authors:  Xueping Chen; Yan Huang; Ting Bao; Fu Jia; Ruwei Ou; Qianqian Wei; Yongping Chen; Jiao Liu; Jing Yang; Huifang Shang
Journal:  Front Aging Neurosci       Date:  2022-01-28       Impact factor: 5.750

3.  Neuropsychological comparison of incident MCI and prevalent MCI.

Authors:  Allison Hansen; Richard J Caselli; Gretchen Schlosser-Covell; Michael A Golafshar; Amylou C Dueck; Bryan K Woodruff; Cynthia M Stonnington; Yonas E Geda; Dona E C Locke
Journal:  Alzheimers Dement (Amst)       Date:  2018-09-27

4.  Development and validation of a clinical model (DREAM-LDL) for post-stroke cognitive impairment at 6 months.

Authors:  Yi Dong; Mengyuan Ding; Mei Cui; Min Fang; Li Gong; Zhuojun Xu; Yue Zhang; Xiuzhe Wang; Xiaofeng Xu; Xueyuan Liu; Gang Li; Yuwu Zhao; Qiang Dong
Journal:  Aging (Albany NY)       Date:  2021-09-10       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.